Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $6.1 million.

  • Ani Pharmaceuticals' Capital Expenditures rose 2682.88% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 704.67%. This contributed to the annual value of $16.2 million for FY2024, which is 8308.53% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Capital Expenditures is $6.1 million, which was up 2682.88% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Capital Expenditures ranged from a high of $6.1 million in Q3 2025 and a low of $356000.0 during Q4 2021
  • For the 5-year period, Ani Pharmaceuticals' Capital Expenditures averaged around $2.6 million, with its median value being $2.4 million (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 8312.8% in 2021, then soared by 78146.07% in 2022.
  • Ani Pharmaceuticals' Capital Expenditures (Quarter) stood at $356000.0 in 2021, then soared by 781.46% to $3.1 million in 2022, then fell by 27.37% to $2.3 million in 2023, then rose by 5.05% to $2.4 million in 2024, then surged by 154.93% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $4.0 million for Q2 2025, and $2.5 million during Q1 2025.